Canada-based SciVac Therapeutics (VAC: TSX) has entered into an agreement and plan of merger to acquire US biotech firm VBI Vaccines (Nasdaq: VBIB) to form a commercial-stage company with a licensed hepatitis B vaccine and a pipeline of preventative and therapeutic vaccine candidates. VBI’s shares leapt 9.3% to $2.61 on the news.
Under the accord, valued at around $92 million, a newly-formed wholly-owned subsidiary of SciVac will merge with and into VBI, with VBI surviving the merger as a wholly-owned subsidiary of SciVac, and SciVac will change its name to VBI Vaccines Inc. At the effective time of the merger, each share of VBI common stock will be converted into the right to receive 20.808356 common shares of SciVac.
Terms of the merger
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze